SCHEMBL6835784

SCHEMBL6835784

CS(=O)(=O)c1nccc(-c2nc(N)sc2C#N)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
GAA P10253 1/20 0.32
MYC P01106 2/20 0.31
WDR5 P61964 2/20 0.31
CYP3A4 P08684 2/20 0.31
EGFR P00533 1/20 0.31
BRAF P15056 1/20 0.31
JAK3 P52333 1/20 0.31
MAPK10 P53779 1/20 0.31
KCNH2 Q12809 1/20 0.31
ERBB4 Q15303 1/20 0.31
CYP2C19 P33261 2/20 0.31
PIK3CD O00329 1/20 0.30
PIP5K1C O60331 1/20 0.30
PIK3CB P42338 1/20 0.30
PI4KA P42356 1/20 0.30
PIK3CG P48736 1/20 0.30
PI4KB Q9UBF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840019 0.79 EGFR (0.33) CYP3A4EGFRBRAFJAK3MAPK10
SCHEMBL6840024 0.76 KDM4E (0.46) KDM4EALDH1A1NPSR1GAAMYC
SCHEMBL6842494 0.76 ALDH1A1 (0.52) KDM4EALDH1A1NPSR1GAACYP3A4
SCHEMBL6839964 0.74 MYC (0.31) KDM4EALDH1A1MYCWDR5SMN1; SMN2
SCHEMBL30309300 0.71 TGFBR1 (0.51) KDM4EALDH1A1GAAPIK3CDPI4KA
SCHEMBL1850971 0.71 TGFBR1 (0.51) KDM4EALDH1A1GAAPIK3CDPI4KA
SCHEMBL6840084 0.71 KDM4B (0.46) KDM4EALDH1A1CYP3A4CYP2C19SMN1; SMN2
SCHEMBL24760933 0.70 CDK2 (0.34) EGFRBRAFJAK3MAPK10PIK3CD
SCHEMBL18230478 0.70 CCR1 (0.49) KDM4EALDH1A1MYCWDR5CYP3A4
SCHEMBL141036 0.70 CDK2 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040181066-A1 Tyrosine kinase inhibitors FRALEY MARK E (US) 2004-09-16 US disclosed
WO-2003011838-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181066-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KDM4E 2200/4885ALDH1A1 3104/4885NPSR1 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.